Bispecific Antibody Hematology Deal Benchmarks

Median Upfront

$717M

Range: $373M - $1.1B

Total Deal Value

$3.6B

Range: $2.2B - $4.9B

Royalty Rate

9% - 16.9%

Tiered up to 20.9%

Dev Milestones

$601M

Range: $388M - $816M

Model Your Deal

Market Analysis

Bispecific antibodies have emerged as a major competitive force in hematologic oncology, challenging CAR-T cell therapy with off-the-shelf convenience and lower manufacturing complexity. Phase 2 bispecific hematology deals carry a median total deal value of $3.6B, with upfront payments of $717M. Approved agents like glofitamab, epcoritamab, and teclistamab have validated the bispecific approach across lymphoma and myeloma.

Deal structures for hematology bispecifics reflect the rapid clinical development timelines and accelerated approval pathways. Development milestones average $601M, regulatory milestones contribute $716M, and commercial milestones reach $1.5B. The overall 20/80 upfront/milestone split reflects moderate clinical risk at Phase 2.

Royalty rates for hematology bispecific deals range from 9% to 16.9%, with escalation to 20.9% on peak sales. Key differentiation factors include subcutaneous versus intravenous formulation, step-up dosing requirements, cytokine release syndrome profile, and activity in CAR-T-refractory patients. Fixed-duration therapy bispecifics command premium terms over continuous treatment approaches.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for hematology bispecific antibodies?

Phase 2 hematology bispecific deals average $717M upfront with $3.6B total deal value. The off-the-shelf advantage over CAR-T therapy supports strong commercial projections and competitive deal economics.

How do bispecific deals compare to CAR-T deals in hematology?

Bispecific antibody deals typically feature lower total deal values than CAR-T programs at equivalent stages, reflecting the less transformative response rates but superior convenience and scalability. However, bispecifics with demonstrated activity in CAR-T-refractory patients can rival CAR-T deal valuations.

Which bispecific targets are most valued in hematology?

CD20xCD3 bispecifics lead in lymphoma (glofitamab, epcoritamab), while BCMAxCD3 approaches target myeloma (teclistamab). Emerging targets include CD123xCD3 for AML, GPRC5DxCD3 for myeloma, and novel T-cell engager formats with reduced CRS risk.

What drives premium valuations for hematology bispecifics?

Premium drivers include subcutaneous formulation (vs. IV), fixed-duration treatment protocols, favorable CRS profiles, activity in earlier lines of therapy, and demonstrated efficacy post-CAR-T. Bispecifics with these attributes can command 15-30% higher total deal values.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Bispecific Antibody Hematology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Hematology Deal Overview

CAR-T Hematology Deals

Bispecific Deals (Oncology)

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?